Laboratory Medicine ›› 2023, Vol. 38 ›› Issue (7): 634-639.DOI: 10.3969/j.issn.1673-8640.2023.07.004
Previous Articles Next Articles
CHEN Ying, LI Wei, LIN Tao, YANG Li
Received:
2022-01-22
Revised:
2023-01-09
Online:
2023-07-30
Published:
2023-09-18
CLC Number:
CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer[J]. Laboratory Medicine, 2023, 38(7): 634-639.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2023.07.004
临床病理特征 | 例数 | PFTK1 | MVD | |||
---|---|---|---|---|---|---|
弱阳性/例 | 中等阳性/例 | 强阳性/例 | 总阳性率/% | |||
性别 | ||||||
女性 | 37 | 8 | 8 | 10 | 70.27 | 38.52±5.25 |
男性 | 51 | 10 | 12 | 14 | 70.59 | 37.14±4.89 |
统计值 | 0.001 | 1.267 | ||||
P值 | 0.975 | 0.209 | ||||
年龄 | ||||||
≤55.6岁 | 46 | 10 | 12 | 11 | 71.74 | 36.85±4.95 |
>55.6岁 | 42 | 8 | 8 | 13 | 69.05 | 38.85±5.02 |
统计值 | 0.076 | 1.880 | ||||
P值 | 0.782 | 0.063 | ||||
TNM分期 | ||||||
Ⅰ~Ⅱ期 | 62 | 14 | 16 | 10 | 64.52 | 31.25±3.58 |
Ⅲ期 | 26 | 4 | 5 | 13 | 84.62 | 45.74±6.85 |
统计值 | 4.606 | 10.217 | ||||
P值 | 0.032 | <0.001 | ||||
淋巴转移 | ||||||
无 | 53 | 13 | 12 | 7 | 60.38 | 30.58±3.89 |
有 | 35 | 5 | 8 | 17 | 85.71 | 46.56±8.42 |
统计值 | 6.501 | 10.512 | ||||
P值 | 0.011 | <0.001 | ||||
病理类型 | ||||||
腺癌 | 62 | 12 | 13 | 19 | 70.97 | 37.59±5.78 |
鳞癌 | 26 | 6 | 7 | 5 | 69.23 | 38.56±5.54 |
统计值 | 0.027 | 0.727 | ||||
P值 | 0.871 | 0.469 | ||||
肿瘤直径 | ||||||
≤3 cm | 42 | 12 | 9 | 4 | 59.52 | 32.54±4.14 |
>3 cm | 46 | 6 | 11 | 20 | 80.43 | 40.28±7.20 |
统计值 | 4.612 | 6.247 | ||||
P值 | 0.032 | <0.001 | ||||
组织学分级 | ||||||
中、高分化 | 73 | 15 | 17 | 21 | 72.60 | 37.58±6.41 |
低分化 | 15 | 3 | 3 | 3 | 60.00 | 39.42±5.52 |
统计值 | 0.441 | 0.972 | ||||
P值 | 0.507 | 0.334 |
临床病理特征 | 例数 | PFTK1 | MVD | |||
---|---|---|---|---|---|---|
弱阳性/例 | 中等阳性/例 | 强阳性/例 | 总阳性率/% | |||
性别 | ||||||
女性 | 37 | 8 | 8 | 10 | 70.27 | 38.52±5.25 |
男性 | 51 | 10 | 12 | 14 | 70.59 | 37.14±4.89 |
统计值 | 0.001 | 1.267 | ||||
P值 | 0.975 | 0.209 | ||||
年龄 | ||||||
≤55.6岁 | 46 | 10 | 12 | 11 | 71.74 | 36.85±4.95 |
>55.6岁 | 42 | 8 | 8 | 13 | 69.05 | 38.85±5.02 |
统计值 | 0.076 | 1.880 | ||||
P值 | 0.782 | 0.063 | ||||
TNM分期 | ||||||
Ⅰ~Ⅱ期 | 62 | 14 | 16 | 10 | 64.52 | 31.25±3.58 |
Ⅲ期 | 26 | 4 | 5 | 13 | 84.62 | 45.74±6.85 |
统计值 | 4.606 | 10.217 | ||||
P值 | 0.032 | <0.001 | ||||
淋巴转移 | ||||||
无 | 53 | 13 | 12 | 7 | 60.38 | 30.58±3.89 |
有 | 35 | 5 | 8 | 17 | 85.71 | 46.56±8.42 |
统计值 | 6.501 | 10.512 | ||||
P值 | 0.011 | <0.001 | ||||
病理类型 | ||||||
腺癌 | 62 | 12 | 13 | 19 | 70.97 | 37.59±5.78 |
鳞癌 | 26 | 6 | 7 | 5 | 69.23 | 38.56±5.54 |
统计值 | 0.027 | 0.727 | ||||
P值 | 0.871 | 0.469 | ||||
肿瘤直径 | ||||||
≤3 cm | 42 | 12 | 9 | 4 | 59.52 | 32.54±4.14 |
>3 cm | 46 | 6 | 11 | 20 | 80.43 | 40.28±7.20 |
统计值 | 4.612 | 6.247 | ||||
P值 | 0.032 | <0.001 | ||||
组织学分级 | ||||||
中、高分化 | 73 | 15 | 17 | 21 | 72.60 | 37.58±6.41 |
低分化 | 15 | 3 | 3 | 3 | 60.00 | 39.42±5.52 |
统计值 | 0.441 | 0.972 | ||||
P值 | 0.507 | 0.334 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
HR值(95%CI) | P值 | HR值(95%CI) | P值 | ||
年龄 | 1.568(0.895~2.698) | 0.265 | |||
性别 | 3.245(2.185~8.265) | 0.562 | |||
TNM分期 | 12.986(6.895~23.654) | <0.001 | 7.256(2.351~21.452) | 0.002 | |
组织学分级 | 3.245(2.185~8.265) | 0.562 | |||
淋巴转移 | 2.315(1.023~3.687) | 0.001 | 2.258(1.052~3.785) | 0.001 | |
病理类型 | 3.025(3.547~10.285) | 0.625 | |||
PFTK1表达 | 5.315(2.689~12.685) | <0.001 | 5.689(1.589~13.254) | <0.001 | |
肿瘤直径 | 3.230(4.258~8.658) | 0.042 | 4.253(3.252~12.586) | 0.012 |
项目 | 单因素分析 | 多因素分析 | |||
---|---|---|---|---|---|
HR值(95%CI) | P值 | HR值(95%CI) | P值 | ||
年龄 | 1.568(0.895~2.698) | 0.265 | |||
性别 | 3.245(2.185~8.265) | 0.562 | |||
TNM分期 | 12.986(6.895~23.654) | <0.001 | 7.256(2.351~21.452) | 0.002 | |
组织学分级 | 3.245(2.185~8.265) | 0.562 | |||
淋巴转移 | 2.315(1.023~3.687) | 0.001 | 2.258(1.052~3.785) | 0.001 | |
病理类型 | 3.025(3.547~10.285) | 0.625 | |||
PFTK1表达 | 5.315(2.689~12.685) | <0.001 | 5.689(1.589~13.254) | <0.001 | |
肿瘤直径 | 3.230(4.258~8.658) | 0.042 | 4.253(3.252~12.586) | 0.012 |
[1] | ALMQUIST D, KHANAL N, SMITH L, et al. Preoperative pulmonary function tests(PFTs) and outcomes from resected early stage non-small cell lung cancer(NSCLC)[J]. Anticancer Res, 2018, 38(5):2903-2907. |
[2] |
HU H, ZHOU Y, ZHANG M, et al. Prognostic value of RASSF1A methylation status in non-small cell lung cancer(NSCLC) patients:a meta-analysis of prospective studies[J]. Biomarkers, 2019, 24(3):207-216.
DOI URL |
[3] | 翟晓然, 江妹, 赵晓婷, 等. PFTK1在人非小细胞肺癌中的表达及临床意义[J]. 癌变·畸变·突变, 2016, 28(3):231-235. |
[4] |
LI J L, YE W T, LIU Z Y, et al. Comparison of microvascular perfusion evaluation among IVIM-DWI,CT perfusion imaging and histological microvessel density in rabbit liver VX2 tumors[J]. Magn Reson Imaging, 2018, 46:64-69.
DOI URL |
[5] |
NTELLAS P, PERIVOLIOTIS K, DADOULI K, et al. Microvessel density as a surrogate prognostic marker in patients with multiple myeloma:a meta-analysis[J]. Acta Haematol, 2017, 138(2):77-84.
DOI URL |
[6] |
陈艺, 张腾龙, 杨哲, 等.IL-33、 肿瘤微血管密度及淋巴管密度在非小细胞肺癌中的表达及对预后的影响[J]. 新医学, 2020, 51(5):370-377.
DOI |
[7] | 李佩文. 肺癌综合诊疗学[M]. 北京: 中国中医药出版社, 2001. |
[8] |
WALIA R, JAIN D, MADAN K, et al. P40 & thyroid transcription factor-1 immunohistochemistry:a useful panel to characterize non-small cell lung carcinoma-not otherwise specified(NSCLC-NOS) category[J]. Indian J Med Res, 2017, 146(1):42-48.
DOI URL |
[9] | 王雪莲, 孙丽华. 弥漫大B细胞淋巴瘤CD68和CD34表达情况及临床价值[J]. 检验医学与临床, 2023, 20(4):518-522. |
[10] |
SAITO Â, SOUZA E E, COSTA F C, et al. Human regulatory protein Ki-1/57 is a target of sumoylation and affects PML nuclear body formation[J]. J Proteome Res, 2017, 16(9):3147-3157.
DOI PMID |
[11] |
MIYAGAKI H, YAMASAKI M, MIYATA H, et al. Overexpression of PFTK1 predicts resistance to chemotherapy in patients with oesophageal squamous cell carcinoma[J]. Br J Cancer, 2012, 106(5):947-954.
DOI |
[12] |
SUN T, CO N N, WONG N. PFTK1 interacts with cyclin Y to activate non-canonical Wnt signaling in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2014, 449(1):163-168.
DOI URL |
[13] |
LIU M H, SHI S M, LI K, et al. Knockdown of PFTK1 expression by RNAi inhibits the proliferation and invasion of human non-small lung adenocarcinoma cells[J]. Oncol Res, 2016, 24(3):181-187.
DOI URL |
[14] | ZHENG L, ZHOU Z, HE Z. Knockdown of PFTK1 inhibits tumor cell proliferation,invasion and epithelial-to-mesenchymal transition in pancreatic cancer[J]. Int J Clin Exp Pathol, 2015, 8(11):14005-14012. |
[15] | 李祚品, 张平安. 血清AFP、TK1、DKK1联合检测对原发性肝癌的诊断价值[J]. 现代中西医结合杂志, 2016, 25(1):94-95. |
[16] | 方堃, 侯红, 王启堂, 等. 胸苷激酶1在良恶性乳腺肿瘤中的表达[J]. 中华内分泌外科杂志, 2017, 11(5):377-379. |
[17] | 杨海杰, 崔阳阳, 王磊, 等. 细胞周期蛋白依赖性激酶PFTK1在少突胶质前体细胞分化中的潜在作用[J]. 中国组织工程研究, 2015, 19(7):1008-1012. |
[18] |
ZHOU Y, JIN G, MI R, et al. Knockdown of P4HA1 inhibits neovascularization via targeting glioma stem cell-endothelial cell transdifferentiation and disrupting vascular basement membrane[J]. Oncotarget, 2017, 8(22):35877-35889.
DOI PMID |
[19] |
LI J, GU J. Cardiovascular toxicities with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients:a meta-analysis of 77 randomized controlled trials[J]. Clin Drug Investig, 2018, 38(12):1109-1123.
DOI |
[20] | 范亚峰, 崔晓燕, 虞中平, 等. Gab2基因在肺癌细胞表达及对癌细胞凋亡及Wnt/β-catenin信号通路的影响[J]. 肿瘤学杂志, 2019, 25(3):213-217. |
[21] | 杨小林. 非小细胞肺癌患者埃兹蛋白、血管抑制蛋白1的表达与微血管密度的相关性研究[J]. 标记免疫分析与临床, 2019, 26(2):259-263. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||